{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:19:03Z","timestamp":1791875943461,"version":"4.3.4"},"reference-count":62,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is suitable for localized cases, sometimes involving lymph node dissection and biopsy, to assess the spread of the disease. Radiation therapy may be sometimes used as a standalone treatment or following surgical excision. Systemic chemotherapy, while having low response rates, is utilized as part of combination treatments or when other methods fail. The development of resistance to systemic chemotherapies and associated side effects have prompted further research and clinical trials for novel approaches. In the case of advanced-stage melanoma, a comprehensive approach may be necessary, incorporating targeted therapies and immunotherapies that demonstrate significant antitumor activity. Targeted therapies, including inhibitors targeting BRAF, MEK, c-KIT, and NRAS, are designed to block the specific molecules responsible for tumor growth. These therapies show promise, particularly in patients with corresponding mutations. Combination therapy, including BRAF and MEK inhibitors, has been evidenced to improve progression-free survival; however, concerns about resistance and cutaneous toxicities highlight the need for close monitoring. Immunotherapies, leveraging tumor-infiltrating lymphocytes and CAR T cells, enhance immune responses. Lifileucel, an FDA-approved tumor-infiltrating lymphocyte therapy, has demonstrated improved response rates in advanced-stage melanoma. Ongoing trials continue to explore the efficacy of CAR T-cell therapy for advanced melanoma. Checkpoint inhibitors targeting CTLA-4 and PD-1 have enhanced outcomes. Emerging IL-2 therapies boost dendritic cells, enhancing anticancer immunity. Oncolytic virus therapy, approved for advanced melanoma, augments treatment efficacy in combination approaches. While immunotherapy has significantly advanced melanoma treatment, its success varies, prompting research into new drugs and factors influencing outcomes. This review provides insights into current melanoma treatments and recent therapeutic advances.<\/jats:p>","DOI":"10.3390\/ph17020214","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T03:47:09Z","timestamp":1707277629000},"page":"214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["A Review of Current and Pipeline Drugs for Treatment of Melanoma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-5607","authenticated-orcid":false,"given":"Nicole","family":"Natarelli","sequence":"first","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Aleman","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella M.","family":"Mark","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine T.","family":"Tran","sequence":"additional","affiliation":[{"name":"School of Medicine, Indiana University, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-2743","authenticated-orcid":false,"given":"Sean","family":"Kwak","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Botto","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaliz","family":"Aflatooni","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Diaz","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York City, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199904293401707","article-title":"The pathogenesis of melanoma induced by ultraviolet radiation","volume":"340","author":"Gilchrest","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.15510","article-title":"The global burden of melanoma: Results from the Global Burden of Disease Study 2015","volume":"177","author":"Karimkhani","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent Advances in the Treatment of Melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"Heistein, J.B., Acharya, U., and Mukkamalla, S.K.R. (2023, April 07). Malignant Melanoma, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470409\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: National cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cps.2021.06.008","article-title":"Emerging Therapies in the Treatment of Advanced Melanoma","volume":"48","author":"Massand","year":"2021","journal-title":"Clin. Plast. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9235638","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_13","first-page":"704","article-title":"Recent Changes and Innovations in Melanoma Treatment: A Review","volume":"11","author":"Sabag","year":"2020","journal-title":"Isr. Med. Assoc. J. IMAJ"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ernst, M., and Giubellino, A. (2022). The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040822"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Steininger, J., Gellrich, F.F., Schulz, A., Westphal, D., Beissert, S., and Meier, F. (2021). Systemic Therapy of Metastatic Melanoma: On the Road to Cure. Cancers, 13.","DOI":"10.3390\/cancers13061430"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of Advanced Melanoma in 2020 and Beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ward, W.H., and Farma, J.M. (2017). Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Eddy, K., and Chen, S. (2020). Overcoming Immune Evasion in Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238984"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1534735421990078","DOI":"10.1177\/1534735421990078","article-title":"Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma","volume":"20","author":"Sood","year":"2021","journal-title":"Integr. Cancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","article-title":"Targeted Therapy and Immunotherapy in Melanoma","volume":"41","author":"Lazaroff","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., and Alos, L. (2021). Molecular Markers and Targets in Melanoma. Cells, 10.","DOI":"10.3390\/cells10092320"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11864-020-0718-2","article-title":"Oncolytic Viruses for the Treatment of Metastatic Melanoma","volume":"21","author":"Trager","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.seminoncol.2023.03.003","article-title":"Improved outcomes in women with BRAF-mutant melanoma treated with BRAF\/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis","volume":"50","author":"Pala","year":"2023","journal-title":"Semin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41586-022-04833-8","article-title":"Androgen receptor blockade promotes response to BRAF\/MEK-targeted therapy","volume":"606","author":"Vellano","year":"2022","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/jdv.18778","article-title":"Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study","volume":"37","author":"Thiem","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., and Scalvenzi, M. (2022). The Treatment of Advanced Melanoma: Therapeutic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126388"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10238-022-00887-0","article-title":"The new progress in cancer immunotherapy","volume":"23","author":"Shimu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1111\/cas.15009","article-title":"Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors","volume":"112","author":"Hirai","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Na\u00efve and Experienced Patients with Metastatic Melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1038\/s41467-020-17011-z","article-title":"Oncolytic virus-derived type I interferon restricts CAR T cell therapy","volume":"11","author":"Evgin","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","article-title":"An engineered IL-2 partial agonist promotes CD8+ T cell stemness","volume":"597","author":"Mo","year":"2021","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/EDBK_321115","article-title":"Adoptive Cellular Therapy for Solid Tumors","volume":"41","author":"Bear","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eabj9779","DOI":"10.1126\/scitranslmed.abj9779","article-title":"Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors","volume":"14","author":"Kaptein","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41586-023-05704-6","article-title":"Targeting TBK1 to overcome resistance to cancer immunotherapy","volume":"615","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1358\/dot.2023.59.2.3509756","article-title":"Nivolumab and relatlimab for the treatment of melanoma","volume":"59","author":"Chen","year":"2023","journal-title":"Drugs Today"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaba5464","DOI":"10.1126\/scitranslmed.aba5464","article-title":"Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity","volume":"12","author":"Raeber","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to Give New Life to T Cell Immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/CBM-190370","article-title":"Serological landscape of cytokines in cutaneous melanoma","volume":"26","author":"Paganelli","year":"2019","journal-title":"Cancer Biomark."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jid.2019.03.1158","article-title":"Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines\/Chemokines in Melanoma Progression","volume":"139","author":"Fang","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1171978","DOI":"10.3389\/fimmu.2023.1171978","article-title":"Expression of lymphoid structure-associated cytokine\/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes","volume":"14","author":"Karapetyan","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients","volume":"10","author":"Samson","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2021.11.002","article-title":"The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma","volume":"241","author":"Zhu","year":"2022","journal-title":"Immunol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., Pala, L., Conforti, F., and Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13061383"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Robinson, C., Xu, M.M., Nair, S.K., Beasley, G.M., and Rhodin, K.E. (2022). Oncolytic viruses in melanoma. Front. Biosci. Landmark Ed., 27.","DOI":"10.31083\/j.fbl2702063"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","article-title":"Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma","volume":"29","author":"Shoushtari","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e005224","DOI":"10.1136\/jitc-2022-005224","article-title":"Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: The phase 1b MITCI study","volume":"10","author":"Curti","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Fernandes GNC (2019). Immunomodulatory Drugs in Melanoma Brain Metastases. Discoveries, 7, e93.","DOI":"10.15190\/d.2019.6"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gracia-Hernandez, M., Munoz, Z., and Villagra, A. (2021). Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. Cancers, 13.","DOI":"10.3390\/cancers13246180"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10555-023-10097-z","article-title":"Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?","volume":"42","author":"Haist","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Elshiaty, M., Schindler, H., and Christopoulos, P. (2021). Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115632"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.1038\/s41598-023-36942-3","article-title":"Fc-competent multispecific PDL-1\/TIGIT\/LAG-3 antibodies potentiate superior anti-tumor T cell response","volume":"13","author":"Yang","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/2\/214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:11Z","timestamp":1760104571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/2\/214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ph17020214"],"URL":"https:\/\/doi.org\/10.3390\/ph17020214","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}